Health Catalyst, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
HCAT$1.44-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of (unaudited) and
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| As ofSeptember 30, | As ofDecember 31, | |
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $40,305 | $249,645 |
| Short-term investments | 51,235 | 142,355 |
| Accounts receivable, net(1) | 60,109 | 57,182 |
| Prepaid expenses and other assets | 13,704 | 16,468 |
| Total current assets | 165,353 | 465,650 |
| Property and equipment, net | 32,609 | 29,394 |
| Intangible assets, net | 89,554 | 86,052 |
| Operating lease right-of-use assets | 7,256 | 12,058 |
| Goodwill | 285,586 | 259,759 |
| Other assets | 6,770 | 6,016 |
| Total assets | $587,128 | $858,929 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,943 | $11,433 |
| Accrued liabilities | 18,644 | 26,340 |
| Deferred revenue(1) | 58,824 | 53,281 |
| Operating lease liabilities | 3,855 | 3,614 |
| Current portion of long-term debt | 1,627 | 231,182 |
| Total current liabilities | 87,893 | 325,850 |
| Long-term debt, net of current portion | 151,512 | 151,178 |
| Deferred revenue, net of current portion | 385 | 249 |
| Operating lease liabilities, net of current portion | 15,125 | 16,291 |
| Contingent consideration liability | 250 | — |
| Other liabilities | 40 | 154 |
| Total liabilities | 255,205 | 493,722 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
|---|---|---|
| Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 70,622,681 and 64,043,799 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 1,604,039 | 1,552,714 |
| Accumulated deficit | (1,273,621) | (1,186,672) |
| Accumulated other comprehensive income (loss) | 1,505 | (835) |
| Total stockholders’ equity | 331,923 | 365,207 |
| Total liabilities and stockholders’ equity | $587,128 | $858,929 |
(1)Includes amounts attributable to related party transactions. See Note 17 for further details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.